Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Mexiletine hydrochloride
Drug ID BADD_D01453
Description Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.
Indications and Usage For the treatment of ventricular tachycardia and symptomatic premature ventricular beats, and prevention of ventricular fibrillation.
Marketing Status approved; investigational
ATC Code C01BB02
DrugBank ID DB00379
KEGG ID D00639
MeSH ID D008801
PubChem ID 21467
TTD Drug ID D0X0RI
NDC Product Code 0093-8739; 10135-730; 65977-0122; 31722-036; 31722-037; 51407-381; 63629-1963; 63629-9180; 0527-4108; 0093-8740; 42291-625; 62756-955; 63629-2145; 72162-1784; 82012-029; 0093-8741; 50742-240; 0527-4109; 63629-1964; 63629-9179; 63629-9181; 63629-9290; 0527-4107; 82012-027; 10135-731; 50742-239; 50742-241; 62756-956; 72166-007; 72162-1783; 42291-624; 51407-380; 62559-820; 62559-821; 82012-028; 10135-732; 73435-007; 31722-038; 62559-822; 72162-1782; 53296-0029; 51927-2953; 42291-626; 62756-957; 17511-136; 46708-871; 51407-379
UNII 606D60IS38
Synonyms Mexiletine | Novo-Mexiletine | Novo Mexiletine | Mexiletine Hydrochloride | Mexitil | Mexitil PL | Mexityl | KO-1173 | KO 1173 | KO1173 | KOE-1173 | KOE 1173 | KOE1173 | Mexiletene
Chemical Information
Molecular Formula C11H18ClNO
CAS Registry Number 5370-01-4
SMILES CC1=C(C(=CC=C1)C)OCC(C)N.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash23.03.13.001--Not Available
Seizure17.12.03.001--
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.003--Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.01.045--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tremor17.01.06.002--
Upper gastrointestinal haemorrhage24.07.02.024; 07.12.02.006--
Urinary hesitation20.02.02.009--Not Available
Urinary retention20.02.02.011--
Ventricular arrhythmia02.03.04.006--
Vision blurred06.02.06.007; 17.17.01.010--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Antinuclear antibody positive13.06.01.003--Not Available
Hot flush21.02.02.001; 08.01.03.027; 24.03.01.005--
Appetite disorder19.09.01.002; 14.03.01.004--Not Available
Laryngeal disorder22.04.01.001--Not Available
Mental disorder19.07.01.002--Not Available
Erectile dysfunction21.03.01.007; 19.08.04.001--
Blood disorder01.05.01.004--Not Available
Abnormal sleep-related event19.02.03.009; 17.15.02.007--Not Available
Psychotic disorder19.03.01.002--
Salivary gland disorder07.06.02.001--Not Available
Pharyngeal disorder22.04.05.007--Not Available
Atrioventricular conduction time shortened02.03.01.014--Not Available
Mucosal disorder08.01.06.029--Not Available
The 3th Page    First    Pre   3    Total 3 Pages